EUVIMEDOpdag EUVIMED
Crossref

Liver Steatosis‐Related Polygenic Risk Score Predicts Hepatocellular Carcinoma Risk After Hepatitis C Virus Eradication

Yu-Sheng Lin, Ying-Cheng Lin, Yun-Yu Chen, Yi-Ming Chen, I-Chieh Chen, Hsin-Ju Tsai, Chia-Chang Chen, Shou-Wu Lee, Hwai-I Yang, Teng-Yu Lee iD

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70566 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2026. Written by Yu-Sheng Lin and 9 co-authors. Institution: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Antiviral Agents, Fatty Liver. 48 references. Funded by: Ministry of Health and Welfare, National Science and Technology Council, Taichung Veterans General Hospital.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Aims Genetic predisposition to hepatic steatosis may increase hepatocellular carcinoma (HCC) risk after hepatitis C virus (HCV) eradication in cirrhotic patients; however, its impact on broader patient populations remains unexplored. We aimed to evaluate the association of steatosis‐polygenic risk score (PRS) with HCC following direct‐acting antiviral (DAA) therapy.

Methods

This retrospective cohort study utilised data from the Taiwan Precision Medicine Initiative, including adults treated with DAAs for HCV. Patients with treatment failure, hepatitis B virus co‐infection, significant alcohol use, or HCC diagnosis prior to sustained virological response at 24 weeks were excluded. All participants underwent genotyping, with PRS‐5 being used to quantify genetic risk. We evaluated the association between PRS‐5 and the risk of incident HCC using restricted cubic spline analysis with Cox proportional hazards models.

Results

The cohort included 420 patients (median age 67.0 years; 46.9% male). The 5‐year cumulative incidence of HCC in PRS‐5 ≥ 0.66 group was higher than PRS‐5 < 0.66 group (23.97%, 95% confidence interval (CI) 7.15%–40.79% vs. 8.89%, 95% CI 5.56%–12.23%; p = 0.014). In multivariable regression, PRS‐5 ≥ 0.66 (aSHR 3.59, 95% CI 1.69–7.63; p < 0.001), body weight index > 24 kg/m 2 (aSHR 2.68, 95% CI 1.24–5.78; p = 0.012), and Fibrosis‐4 index > 3.25 (aSHR 4.58, 95% CI 2.20–9.53; p < 0.001) were independently associated with HCC occurrence. Subgroup analysis supported the predictive value of PRS‐5 in almost all patient subgroups, including Fibrosis‐4 index < 3.25 and non‐cirrhosis.

Conclusions

PRS‐5 is independently associated with increased HCC risk after HCV eradication, supporting its role in personalised HCC surveillance strategies.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntiviral AgentsFatty LiverHepatitis C, ChronicHumansFemaleMaleRetrospective StudiesGenetic Risk ScoreMiddle AgedAgedTaiwanRisk FactorsGenetic Predisposition to DiseaseGenotypeIncidenceProportional Hazards Models

Author keywords

antiviral agentsgenetic risk scorehepatitis Chepatocellular carcinoma

Substances

Antiviral Agents

Authors and institutions

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, Chung Hsing University, Taichung, Taiwan.
  • Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Heart Rhythm Center and Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

ORCID profiles: Teng-Yu Lee

Funding

  • Ministry of Health and Welfare
  • National Science and Technology Council
  • Taichung Veterans General Hospital

Cite

APA

Lin, Y. S., Lin, Y. C., Chen, Y. Y., Chen, Y. M., Chen, I. C., Tsai, H. J., Chen, C. C., Lee, S. W., Yang, H. I., & Lee, T. Y. (2026). Liver Steatosis‐Related Polygenic Risk Score Predicts Hepatocellular Carcinoma Risk After Hepatitis C Virus Eradication. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70566

Vancouver

Lin YS, Lin YC, Chen YY, Chen YM, Chen IC, Tsai HJ, et al. Liver Steatosis‐Related Polygenic Risk Score Predicts Hepatocellular Carcinoma Risk After Hepatitis C Virus Eradication. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70566

BibTeX
@article{Lin2026,
  author = {Lin, Yu-Sheng and Lin, Ying-Cheng and Chen, Yun-Yu and Chen, Yi-Ming and Chen, I-Chieh and Tsai, Hsin-Ju and Chen, Chia-Chang and Lee, Shou-Wu and Yang, Hwai-I and Lee, Teng-Yu},
  title = {Liver Steatosis‐Related Polygenic Risk Score Predicts Hepatocellular Carcinoma Risk After Hepatitis C Virus Eradication},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70566}
}
Start for free →